subject: Promotion Of The New Richest Man, Li Li Hai Purui: How To Make Fortune 42.6 Billion - Hai Purui - [print this page] Haipu Rui (002399.SZ) released high price, the new richest man, Li Li, turned from the sky.
Li Li From April 26, Hai Purui per share offering price of 148 yuan, which few people know of the biological family Medicine Almost all of the company broke into the eyes of investors. Its founder, Li Li, Li Tanfu women's total holding 28,803.7 million shares, to issue price of its net worth was 42.629 billion yuan, topped the mainland's richest man.
This is a classic private family business, actually controlled by Li Li, Li Tanfu women, two were appointed chairman and director Haipu Rui, deputy general manager, director, general manager of single-Yu Tan's elder brother Lee.
1998, Li Li co-founded Hai Purui their families, and hard not started in this business, 10 years earlier, wandering in Sichuan, Chongqing, Li Li, a time to search for products and solution production run into a wall or compromises, and finally, the opportunity and the Southwest from a medicine Cooperation Li Li uncovered pot of gold.
Bodiless Chongqing China Star 1997 12 26, southwest of medicine will be transferred to the respective pharmaceutical West Chongqing Chongqing Begonia New Materials Co., Ltd., was 23.2 million yuan transfer payments for the formation of bio-technology Co., Ltd.. That year, 1997, Southwest Pharmaceutical raise funds through placement of shares 34.79 million yuan.
Journalists access to information learned, Southwest Pharmaceutical Products joint venture established biotechnology companies in Chongqing huaxing biological technology limited liability company, registered capital of 50 million yuan. Southwest Pharmaceutical companies which invested 34 million yuan, accounting for 68% of shares; Chongqing Huayin Lease Co., Ltd. invested 15 million yuan, accounting for 30% of the shares, while another partner for the Chongqing Tongda Biological Products Co., Ltd., invested one million yuan accounted for only 2% ratio. Southwest Pharmaceutical
year according to the notice said, Chongqing huaxing biological main biological products, pharmaceutical technology, product development, from marketing and technical services Chemical industry Products and raw materials, medical devices and equipment.
Chongqing Li Li accessible biological products shall be the first business platform. According to business information in Chongqing, Chongqing Tongda Biological Products Co., Ltd. was established in 1990, the legal representative of the Li Li, location for the Jiulongpo District Branch Chong Road, No. 6, registered business scope is currently the main Haipu Rui Pharma business operations: production, Sell Heparin sodium API.
Li Li was born in 1964, in July 1987 graduated from the Department of Chemistry, Sichuan University, Chengdu, meat processing before being assigned to work.
1992 10 months, Li Li leave the state-owned units, cooperation with the Chongqing Tongda heparin contracting projects. Chongqing Tongda Trade Co., Ltd. in Chongqing China Shanghai, Chongqing City Construction Investment Corporation of Shenzhen City, China Business Sources Joint Industrial Development Co., Ltd. and Hong Kong co-Shun Industrial Co., Ltd., Chongqing Kebo Technology Co., Ltd. jointly established by Li Li is directly responsible for management, served as chief engineer, chairman and managing director. According to China Securities
pharmaceutical analyst Jin Hao Pei-yu's research and analysis on the end of the century the rise of modern biotechnology and micro- Electronic Technology, new materials and new energy technologies are considered the core of 21st century science. The development of modern biotechnology to the development of the pharmaceutical industry was opened up a new whole new areas. Since 1995, the majority of domestic pharmaceutical companies are attracted into the field. Southwest Pharmaceutical
According to public information display, Chongqing huaxing material that is year 1998 profit of 3.28 million yuan. October 2000, Southwest Pharmaceutical increase biopharmaceutical investment, joint venture invested 3,687,600 yuan acquisition of innovative bio-engineering Co., Ltd. Chongqing, representing the total shares of joint venture 65% of Singaporean Chinese Cui Taian funding equivalent to 150 million, composed of proprietary technologies and equipment as investment, accounting for the remaining 35% stake.
Chongqing Chongqing huaxing biological and bio-innovation with the office, staff from the same class leadership and management, after 2000 gradually involved in litigation with the Southwest medicine, there is no Qingli business.
"Chongqing huaxing material was mainly to do some biomedical research, no real business was already." Southwest Pharmaceutical securities Zhou Xia said. In 2008, despite the Chongqing huaxing biological systems by the Chongqing Science and Technology Committee approved hi-tech enterprises, 15% of the income tax concessions apply to the southwest medicine only dividends from the company 172,889 yuan.
